TGV-Inhalonix announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to its new drug candidate, Mul-1867, for the treatment of antibiotic-resistant bacterial lung infections in patients with cystic fibrosis.
The designation was granted by the FDA after reviewing multiple experimental research findings by the company. Mul-1867 data have been published in several scientific journals and were presented at major microbiology and infectious disease conferences.
Mul-1867 is an inhaled antimicrobial agent under development for the treatment of pulmonary infections caused by multidrug-resistant bacteria.
For more information visit TGV-inhalonix.com.